Progyny's Buy Rating Affirmed: Strategic Growth Potential Outweighs Setbacks
Analysts Have Conflicting Sentiments on These Healthcare Companies: 4D Molecular Therapeutics (FDMT) and Progyny (PGNY)
BTIG Maintains Progyny(PGNY.US) With Hold Rating
Analysts Offer Insights on Healthcare Companies: Progyny (PGNY) and Roivant Sciences (ROIV)
Progyny Analyst Ratings
Barclays Maintains Progyny(PGNY.US) With Buy Rating, Maintains Target Price $30
Barclays Reaffirms Their Buy Rating on Progyny (PGNY)
JMP Securities Downgrades Progyny(PGNY.US) to Hold Rating
Progyny Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on Progyny, Maintains $37 Price Target
Truist Financial Maintains Progyny(PGNY.US) With Buy Rating
Progyny Analyst Ratings
J.P. Morgan Maintains Progyny(PGNY.US) With Buy Rating, Announces Target Price $31
Analysts Offer Insights on Healthcare Companies: Sanofi (OtherSNYNF), Progyny (PGNY) and Health Catalyst (HCAT)
A Quick Look at Today's Ratings for Progyny(PGNY.US), With a Forecast Between $25 to $31
A Quick Look at Today's Ratings for Progyny(PGNY.US), With a Forecast Between $24 to $31
Progyny: Growth Potential Acknowledged Amid Execution Concerns – Hold Rating Maintained
Progyny (PGNY) Gets a Buy From Barclays
Progyny's Growth Trajectory and Market Differentiation Affirm Buy Rating
Progyny Analyst Ratings